- Current report filing (8-K)
25 April 2009 - 6:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
April 20, 2009
Date of Report
(Date of earliest event reported)
MIDDLEBROOK PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-50414
|
|
52-2208264
|
|
|
|
|
|
(State or Other
|
|
(Commission File Number)
|
|
(IRS Employer
|
Jurisdiction of
|
|
|
|
Identification No.)
|
Incorporation)
|
|
|
|
|
7
Village Circle, Suite 100, Westlake, Texas 76262
(Address of Principal Executive Offices) (ZIP Code)
Registrants telephone number, including area code:
(817) 837-1200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13a-4(c))
|
|
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
|
On April 20, 2009, Wayne T. Hockmeyer, Ph.D., a member of our Board of Directors and Chair of
our Compensation Committee, formally notified us of his decision not to stand for re-election at
our upcoming annual meeting of stockholders scheduled for June 23, 2009. Dr. Hockmeyer will
continue to serve until his term expires at our 2009 annual meeting. The decision by Dr. Hockmeyer
not to stand for re-election was not the result of any disagreement with MiddleBrook
Pharmaceuticals, Inc.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
MIDDLEBROOK PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
Date: April 24, 2009
|
|
By:
|
|
/s/ Dave Becker
Dave Becker
|
|
|
|
|
|
|
Executive Vice President and
|
|
|
|
|
|
|
Chief Financial Officer
|
|
|
3
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Middlebrook Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More News Articles